enfuvirtid
enf
clinic
use
peptid
drug
treatment
hiv
infect
poor
pharmacokinet
profil
h
rat
low
aqueou
solubl
make
therapi
expens
inconveni
studi
present
simpl
practic
strategi
address
problem
conjug
enf
polyethylen
glycol
peg
sitespecif
attach
kda
peg
nterminu
enf
result
ep
conjug
high
solubl
mgml
long
halflif
rat
h
conjug
show
similar
antivir
activ
enf
variou
primari
isol
ec
nm
mechanist
studi
suggest
sourc
antivir
potenc
conjug
bound
function
domain
hiv
protein
helic
conform
high
affin
k
nm
therebi
inhibit
fusion
viral
hostcel
membran
peg
conjug
advanc
mani
bioactiv
protein
peptid
clinic
applic
ep
conjug
describ
repres
potenti
new
treatment
hiv
infect
may
address
unmet
medic
need
associ
current
enf
therapi
highli
activ
antiretrovir
therapi
haart
allow
simultan
administr
multipl
drug
current
standard
treatment
hiv
infect
drug
combin
use
set
normal
consist
sever
inhibitor
target
differ
enzym
viral
lifecycl
includ
revers
transcriptas
proteas
integras
although
haart
dramat
decreas
level
morbid
mortal
associ
hiv
infect
emerg
drug
resist
usual
unavoid
high
mutat
rapid
replic
rate
viru
sequenti
administr
differ
drug
therefor
requir
treatment
hiv
infect
well
develop
new
target
therapi
enfuvirtid
enf
import
choic
treatment
patient
respond
well
haart
contrast
tradit
smallmolecul
enzym
inhibitor
enf
peptid
bind
viral
envelop
protein
inhibit
membran
fusion
viru
hostcel
essenti
step
deliveri
viral
genom
cell
enf
success
use
clinic
practic
control
hiv
infect
transmiss
howev
case
mani
peptid
protein
drug
enf
exhibit
poor
aqueou
solubl
rapidli
remov
system
circul
metabol
pathway
immun
respons
system
maintain
efficaci
concentr
enf
must
administ
twice
daili
high
dosag
mg
subcutan
inject
furthermor
enf
therapi
must
implement
consist
extend
period
time
chronic
natur
hiv
infect
lead
sever
injectionsit
reaction
enf
treatment
therefor
inconveni
patient
repres
expens
regimen
health
care
provid
factor
sever
limit
applic
clinic
number
differ
approach
develop
address
pharmacokinet
problem
associ
enf
sever
peptid
analogu
inhibit
hiv
fusion
similar
manner
peptid
engin
strategi
incorpor
salt
bridg
lead
increas
vivo
stabil
peptid
sequenc
result
extend
halfliv
chemic
modif
peptid
synthet
natur
molecul
cholesterol
albumin
also
lead
reduct
immunogen
proteolysi
polyethylen
glycol
peg
conjug
commonli
use
method
improv
pharmacokinet
therapeut
peptid
protein
method
appli
peptid
inhibitor
hiv
fusion
overlap
enf
residu
pegyl
peptid
show
increas
halflif
tryptic
degrad
although
slight
decreas
fusioninhibitori
potenc
compar
unmodifi
peptid
despit
posit
result
report
studi
pegyl
inhibitor
report
literatur
date
pertain
antivir
activ
pharmacokinet
properti
fusion
inhibitor
conjug
peg
part
ongo
research
toward
develop
persist
inhibitor
hiv
fusion
previous
develop
seri
glycosyl
enf
long
vivo
halfliv
complet
retain
antivir
activ
similar
manner
pegyl
glycosyl
peptid
protein
lead
increas
molecular
size
steric
bulk
signific
impact
biophys
physiolog
properti
howev
current
techniqu
construct
glycopeptid
glycoprotein
quit
challeng
recombin
express
system
allow
rapid
largescal
product
glycopeptid
glycoprotein
system
provid
limit
control
glycosyl
step
chemic
chemoenzymat
synthes
produc
structur
welldefin
molecul
gener
requir
multipl
step
tediou
purif
procedur
result
low
product
yield
therebi
limit
practic
applic
base
previou
experi
glycosyl
enf
fact
pegyl
advanc
mani
bioactiv
protein
peptid
clinic
applic
sought
prepar
ep
conjug
simpl
altern
control
modif
site
enf
molecular
weight
mw
peg
success
synthes
ep
conjug
remark
improv
pharmacokinet
profil
conjug
form
strong
bind
interact
function
fragment
protein
exhibit
potent
inhibitori
activ
toward
variou
hiv
isol
current
circul
vitro
efficaci
compar
enf
therefor
envisag
result
present
studi
provid
basi
develop
ep
conjug
longlast
hiv
fusion
inhibitor
treatment
hiv
infect
follow
establish
glycosyl
strategi
investig
sitespecif
addit
peg
terminu
enf
use
thiolmaleimid
coupl
reaction
fig
two
enf
deriv
bear
singl
cystein
residu
ctermini
cenf
enfc
modifi
methoxypegmaleimid
mpegmal
kda
reaction
proceed
smoothli
nearphysiolog
condit
give
correspond
ep
conjug
bear
fulli
intact
enf
sequenc
conjug
purifi
prepar
hplc
follow
lyophil
result
residu
give
desir
product
white
powder
yield
puriti
subsequ
character
conjug
malditof
ms
reveal
singl
defin
attach
peg
peptid
backbon
expect
conjug
highli
solubl
water
mgml
oppos
enf
neglig
aqueou
solubl
ensur
modifi
enf
retain
bind
affin
hiv
protein
measur
strength
bind
interact
conjug
function
fragment
known
contain
full
bind
region
enf
use
suitabl
model
investig
hiv
fusion
inhibitor
surfac
plasmon
reson
spr
experi
show
conjug
strongli
bound
affin
k
rang
nm
fig
although
affin
conjug
lower
enf
nm
observ
gener
trend
toward
increas
affin
mw
peg
portion
conjug
decreas
particularli
demonstr
affin
nm
approxim
enf
contrast
none
ep
conjug
enf
bound
bovin
serum
albumin
bsa
confirm
observ
interact
specif
peptid
spr
experi
measur
bind
enf
ep
conjug
chipimmobil
assay
condit
exactli
match
membran
environ
necessari
fusion
inhibit
howev
potent
interact
ep
conjug
confirm
assay
suggest
attach
peg
signific
impact
intrins
bind
affin
enf
peptid
conform
remark
effect
antivir
activ
fusion
inhibitor
enf
lack
defin
structur
solut
low
ahel
contrast
adopt
typic
ahel
conform
solut
ahel
reduc
dramat
upon
bind
enf
enf
ep
conjug
prepar
studi
analyz
circular
dichroism
cd
result
reveal
low
ahel
content
enf
decreas
attach
peg
mwdepend
manner
fig
interestingli
conjug
interact
form
stabl
ahel
complex
markedli
higher
ahel
alon
complex
enf
fig
result
howev
inconsist
affin
conjug
obvious
lower
enf
ahel
bind
complex
posit
correl
stabil
appar
contradict
affin
ahel
like
result
differ
assay
format
unlik
chipbas
spr
assay
immobil
solid
surfac
cd
experi
free
ep
conjug
solut
abl
partak
dynam
bind
process
allow
attach
peg
interact
bind
complex
aqueou
medium
mechan
improv
ahel
complex
follow
pegyl
yet
determin
howev
abil
attach
peg
form
amphiphil
shell
capabl
stabil
coiledcoil
peptid
core
aqueou
condit
may
provid
evid
support
result
establish
ep
conjug
could
bind
fragment
form
high
affin
complex
high
ahel
examin
antivir
activ
laboratoryadapt
strain
replic
viru
tzmbl
cell
measur
presenc
conjug
enf
control
tabl
enf
conjug
inhibit
replic
hiv
nanomolar
concentr
cytotox
observ
micromolar
rang
cc
mm
determin
use
xtt
assay
two
conjug
bear
smaller
peg
kda
show
higher
activ
kda
counterpart
ntermin
pegyl
peptid
show
much
greater
activ
ctermin
congen
exhibit
highest
inhibitori
activ
fig
bind
kinet
paramet
tabl
calcul
use
biacor
analysi
softwar
sequenc
follow
tltvqarqllsgivqqqnnllraieaqqhllqltvwgikqlqaril
fig
cd
spectra
enf
ep
conjug
pb
buffer
ph
c
ahel
calcul
rel
ellipt
valu
cm
dmol
nm
assum
correspond
helic
content
detail
see
tabl
absenc
peptid
enf
conjug
adopt
random
coil
structur
b
presenc
equimolar
amount
complex
show
much
lower
ahel
wherea
ep
complex
fulli
ahel
ellipt
cm
dmol
nm
conjug
notabl
ec
valu
nm
compar
enf
nm
chemic
modif
cterminu
enf
advers
impact
antivir
activ
lipophil
residu
wnwf
region
requir
anchor
peptid
membran
interfac
fusion
occur
data
therefor
agreement
earlier
find
reveal
attach
nterminu
enf
lead
signific
decreas
antivir
efficaci
next
analyz
pharmacokinet
rat
follow
subcutan
inject
singl
dose
materi
fig
contrast
enf
rapidli
adsorb
rapidli
clear
system
circul
ep
conjug
show
slower
sustain
releas
profil
inject
site
calcul
pharmacokinet
paramet
use
wellestablish
noncompartment
method
reveal
conjug
elimin
halflif
longer
enf
overal
pharmacokinet
profil
also
superior
enf
mark
increas
area
plasma
concentr
time
curv
auc
appar
volum
distribut
v
mean
resid
time
mrt
well
mark
decreas
systemat
clearanc
rate
cl
improv
pharmacokinet
profil
gener
seen
mani
pegyl
protein
peptid
therapeut
make
ep
conjug
attract
longlast
fusion
inhibitor
address
unmet
medic
need
associ
treatment
hiv
infect
evalu
therapeut
potenti
examin
antivir
spectrum
use
fourteen
virus
differ
subtyp
includ
five
b
also
known
thai
b
five
bc
four
ae
isol
repres
predomin
strain
current
circul
china
inhibit
replic
virus
tzmbl
cell
efficaci
enf
activ
ec
lownanomolar
rang
tabl
select
indic
si
greater
taken
togeth
remark
improv
pharmacokinet
properti
broad
potent
antivir
activ
show
ep
conjug
warrant
preclin
clinic
evalu
demonstr
sitespecif
pegyl
enf
improv
pharmacokinet
profil
without
discern
decreas
antivir
activ
coupl
cenf
mpegmal
concis
thiolmaleimid
reaction
allow
largescal
synthesi
ep
conjug
could
import
clinic
applic
requir
suffici
suppli
materi
ep
conjug
exhibit
much
better
aqueou
solubl
vivo
halflif
enf
could
lead
lessfrequ
dose
regimen
reduct
advers
injectionsit
reaction
addit
ep
conjug
display
potent
inhibitori
activ
toward
common
primari
hiv
strain
circul
china
highlight
potenti
effect
longact
inhibitor
hiv
fusion
noteworthi
number
envelop
virus
includ
ebola
viru
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
error
bar
indic
sd
b
pharmacokinet
paramet
valu
calcul
use
noncompartment
analysi
nca
winnonlin
version
pharsight
cari
nc
express
mean
valu
sd
elimin
halflif
termin
halflif
refer
time
requir
concentr
remain
drug
plasma
reduc
pseudoequilibrium
drug
distribut
bodi
reach
peptid
use
studi
synthes
use
solidphas
fmoc
method
beij
scilight
biotechnolog
llc
beij
china
purifi
hplc
puriti
character
ms
sourc
tzmbl
well
method
use
preserv
passag
describ
previous
clinic
isol
subtyp
b
bc
ae
obtain
treatmentna
patient
store
laboratori
chines
center
diseas
control
prevent
virus
repres
predomin
strain
circul
china
spraguedawley
rat
male
week
old
g
purchas
beij
hfk
bioscienc
beij
china
fed
day
use
pharmacokinet
analysi
mpegmal
kda
purchas
beij
kaizheng
biotech
develop
beij
china
chemic
use
studi
purchas
analyt
grade
variou
commerci
sourc
hplc
analys
perform
agil
system
agil
usa
equip
uv
detector
malditof
mass
spectra
record
bruker
biflex
iii
spectromet
bruker
dalton
germani
experi
virus
perform
approv
biosafeti
level
contain
laboratori
aqueou
solut
disodium
hydrogen
phosphat
mm
ad
dropwis
manner
stir
mixtur
cysteineincorpor
enf
cenf
enfc
mg
mmol
mpegmal
kda
equiv
sodium
phosphat
buffer
ml
mm
ph
adjust
ph
mixtur
result
mixtur
stir
min
rt
directli
purifi
prepar
hplc
afford
mg
mg
mg
mg
white
powder
hplc
chromatograph
condit
provid
fig
bind
affin
ep
conjug
peptid
analyz
biacor
biosensor
system
biacor
biacor
co
ltd
sweden
use
previous
describ
procedur
briefli
immobil
carboxymethyl
dextranco
sensor
chip
research
grade
use
standard
primari
aminecoupl
protocol
solut
ep
conjug
pb
contain
tween
vv
differ
concentr
mm
flow
surfac
sensor
rate
ml
min
respons
record
enf
use
posit
control
instead
ep
conjug
bsa
use
neg
control
instead
peptid
bind
kinet
paramet
calcul
use
biacor
evalu
softwar
version
result
shown
tabl
secondari
structur
enf
ep
conjug
analyz
absenc
presenc
peptid
use
chirascan
spectropolarimet
appli
photophys
ltd
uk
measur
conduct
use
solut
peptid
pb
mm
ph
describ
previous
concentr
mm
use
enfep
conjug
peptid
antivir
activ
enf
ep
conjug
laboratoryadapt
clinic
isol
subtyp
b
bc
ae
determin
tzmbl
cell
cultur
describ
previous
briefli
tzmbl
cell
grown
tissu
cultur
plate
well
inocul
tcid
viru
presenc
absenc
enf
ep
conjug
ml
dmem
differ
concentr
nm
incub
c
h
cell
ml
harvest
lyse
use
lyse
reagent
ml
promega
activ
luciferas
express
tzmbl
cell
measur
ec
ec
valu
calcul
use
reed
muench
method
base
percentag
inhibit
luciferas
activ
cytotox
ep
conjug
measur
tzmbl
cell
follow
standard
xtt
assay
protocol
spraguedawley
rat
n
given
singl
subcutan
inject
enf
dosag
mmolkg
physiolog
salin
collect
process
blood
sampl
determin
peptid
concentr
evalu
pharmacokinet
perform
describ
previous
known
hplc
method
use
identifi
plasma
concentr
enf
hplc
condit
follow
water
rphplc
column
xselect
csh
mm
mm
water
ch
cnh
contain
vv
tfa
gradient
mlmin
uv
detect
nm
